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Abstract
Background—Depression is associated with poor adherence to medications and worse
prognosis in patients with acute coronary syndrome (ACS).
Purpose—To determine whether cognitive, behavioral, and/or psychosocial vulnerabilities for
depression explain the association between depression and medication adherence among ACS
patients.
Methods—169 ACS patients who agreed to have their aspirin adherence measured using an
electronic pill bottle for 3 months were enrolled within 1 week of hospitalization. Linear
regression was used to determine whether depression vulnerabilities predicted aspirin adherence
after adjustment for depressive symptoms, demographics, and comorbidity.
Results—Of the depression vulnerabilities, only role transitions (beta = −3.32; p=0.02) and
interpersonal conflict (beta −3.78; p=0.03) predicted poor adherence. Depression vulnerabilities
did not mediate the association between depressive symptoms and medication adherence.
Conclusions—Key elements of the psychosocial context preceding the ACS including major
role transitions and conflict with close contacts place ACS patients at increased risk for poor
medication adherence independent of depressive symptoms.
Keywords
medication adherence; depression; acute coronary syndrome; interpersonal conflict; role
transitions
Background
Depression after acute coronary syndrome (ACS; unstable angina and myocardial infarction)
is an established risk factor for poor prognosis. ACS patients with elevated depressive
symptoms have approximately twice the risk of ACS recurrence or mortality.(1–3) One
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mechanism postulated to mediate the association between depression and prognosis after
ACS is poor adherence to cardiovascular medications. There is a strong, consistent
relationship between depression and poor medication adherence in cardiovascular(4, 5) and
other medical populations.(6) Even patients with mild depressive symptoms are at risk for
poor adherence.(4) Poor adherence to cardiovascular medications has been associated with
poor prognosis(7, 8), and in one study, we have shown that poor adherence to aspirin
appears to partially mediate the association between depression and prognosis after ACS.(9)
Despite the strong association between depression and poor adherence, interventions to
improve depressive symptoms have not led to reliable improvements in medication
adherence, even when these interventions have successfully reduced depressive symptoms.
(10, 11) Accordingly, there is still a need to better understand the association between
depression and poor adherence to medications.
Depression is a multifaceted psychological disorder that arises from a combination of
genetic, biological, and environmental factors in patients with underlying vulnerabilities.
(12) These vulnerabilities can be grouped into behavioral, cognitive, and/or psychosocial
elements that predispose individuals to developing depression. We have previously explored
the intercorrelations and prevalence of these three categories of vulnerability in post-ACS
patients. We showed that the intercorrelations between these vulnerabilities were low and
that there was a higher prevalence of each vulnerability in depressed as compared to non-
depressed patients.(13) Each of these more trait-like vulnerabilities has the potential to
influence adherence behavior. For example, patients who are not sufficiently behaviorally
activated to schedule pleasurable activities may have low overall motivation for self-care
activities including medication adherence. Patients with maladaptive cognitive schema may
hold dysfunctional attitudes about the risks and benefits of medications that in turn lead
them to not adhere to their regimens. Finally, patients who experience vulnerabilities in their
psychosocial milieu either in the form of interpersonal conflicts with their partners or major
life events may have lower adherence due to limitations in social support or disruptions in
habits that support medication adherence. A better understanding as to which of these
underlying depression vulnerabilities is associated with adherence and whether they mediate
the effect of depressive symptoms on adherence may inform the development of
interventions to improve medication adherence among patients with depression.
Accordingly, we tested the association of depression to medication adherence with and
without including depression vulnerabilities in a model predicting medication adherence.
We hypothesized that when depression vulnerabilities were added to the model, the
association between depression and adherence would be mediated, at least in part, by one or
more of the depression vulnerabilities.
Methods
Patients
The current analyses utilized data from the Coronary Psychosocial Evaluation Studies
(COPES), a series of multi-site observational cohort studies that concern the relationship
between depression and prognosis after ACS.(14) To be included in COPES, patients had to
be hospitalized for an ACS and have a score on the Beck Depression Inventory (BDI) of <5
or ≥10, ranges selected to delineate not depressed and depressed status at the time of
hospitalization for an ACS. Patients were excluded if they lived in a nursing home, exhibited
cognitive impairment, or engaged in alcohol or substance abuse. A subset of patients who
were prescribed aspirin had their adherence assessed by an electronic pill cap (N=172), and
these patients are included here. The study was approved by the Institutional Review Boards
at each participating hospital and all patients provided informed consent prior to enrollment
and data collection.
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Details regarding enrollment into COPES have been described elsewhere.(5) Briefly,
between May 1, 2003 and April 15, 2005, patients were recruited from 3 academic hospitals
(Yale-New Haven Hospital and Hospital of St. Raphael in New Haven CT; Mount Sinai
Hospital in New York City) within 1 week of hospitalization for an ACS, defined as either
acute myocardial infarction (MI) or unstable angina using standard criteria.(15) A
cardiologist confirmed ACS eligibility for all patients. In addition to depression eligibility
being determined by BDI, patients completed questionnaire assessment of depression
vulnerabilities and other key study measures. Upon hospital discharge, patients were
provided with a 90-day supply of their prescribed aspirin in a Medication Event Monitoring
System (MEMS; APREX Corp, Fremont, CA) bottle. At 3 month follow-up, patients
returned the MEMS bottle cap.
Measures
Medication adherence—The MEMS device contains an electronic chip in the bottle cap
that records the date and time whenever the bottle cap is opened. MEMS data were collected
continuously over the 3 months following discharge for the index ACS event. The
percentage of days the bottle cap was opened the correct number of times (once a day) was
calculated.
Depression Vulnerabilities
1. Cognitive Vulnerability—We used the 24-item version of the Dysfunctional Attitudes
Scale (DAS-24) to measure attitudes and beliefs that represent a cognitive vulnerability to
depression.(16, 17) Sample items include: “If others dislike you, you cannot be happy” and
“If a person asks for help, it is a sign of a weak person”. Items are rated on a 7-point scale
ranging from 1 (totally agree) to 7 (totally disagree). Scores were recoded so that higher
scores indicate higher levels of cognitive dysfunction. No time period for holding these
attitudes is specified for this measure. The measure had good internal consistency (Cronbach
α = 0.84).
2. Behavioral Vulnerability—We used the 20-item short version of the Pleasant Events
Schedule for the Elderly (PES-E) to assess behavioral vulnerability to depression.(18) On
the PES-E participants indicate how frequently they engaged in or had experienced each of
20 pleasant events during the past month. Answer options are 0 (not at all), 1 (1–6 times)
and 2 (≥7 times). Missing items were coded as ‘0’ if at least 50% of the 20 items had been
answered. Items were recoded so that higher scores indicate infrequency of pleasant events.
There was good internal consistency with this measure (Cronbach α = 0.84).
3. Psychosocial Vulnerability
i. Role Transitions: We generated a list of role transitions based on the Interpersonal
Problem Area Rating Scale(19) to assess social vulnerability to depression. Potential role
transitions included geographic move, marriage or cohabitation, separation or divorce,
graduation or new job, loss of job or retirement, and health problems other than coronary
heart disease. Participants were asked to indicate whether they had experienced any of these
events within the past year. They were also asked to name any other significant positive or
negative events that had occurred within the past year. Items were summed to provide the
total number of role transitions, not including heart disease, in the year prior to the ACS.
ii. Interpersonal Conflict: We used questions from the Dyadic Adjustment scale to assess
interpersonal conflict.(20) Patients are asked to name the one person closest to them and to
rate the extent to which they agreed or disagreed with that person on 15 important issues
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(e.g., handling finances, making major decisions, friends, or philosophy of life). Answers
range from 1 (always disagree) to 6 (always agree). Scores were recoded such that higher
scores reflected higher disagreement and a mean score was calculated so long as patients
had provided responses to at least 6 items. The measure had good internal consistency
(Cronbach α = 0.92).
Depressive Symptoms—We measured depressive symptoms using the Beck Depression
Inventory (BDI).(21) The BDI consists of 21 items describing cognitive-affective and
somatic depression symptoms. Patients rate the extent to which each symptom had been
present in the prior week on a 4-point scale (0–3). The BDI has been used in prior studies of
depression and ACS, and elevated scores predict shorter post-ACS event-free survival.(22)
A score ≥ 10 is consistent with at least mild to moderate depression. The BDI had good
internal reliability (Cronbach α = 0.90) in our sample.
Covariates—Baseline demographics and clinical variables, including the constituents of
the Charlson comorbidity index, a validated measure of risk for death in patients with
chronic illness,(23) were obtained by patient interview and chart abstraction at the time of
enrollment.
Analytic Plan
In cases of partial missing data on depression vulnerability scales, total scores were imputed
from the subset of answered questions using a regression based approach so long as the total
R-squared of the regression equation predicting the total score was >75%. This approach led
to three participants missing data on the Dyadic Disagreement scale. One of these three
participants was also missing data pertinent to role transitions. Only patients with data for all
of the vulnerabilities were included in these analyses such that the total sample was
comprised of 169 patients.
As per convention in cardiovascular adherence studies, patients were defined as poor
adherers if they took their aspirin correctly on fewer than 80% of days monitored.(24)
Patient characteristics were then compared according to adherence status, using chi-squared
tests for proportions and t-tests for normally distributed continuous variables. Homogeneity
of variance was assessed when determining whether data was normally distributed. In cases
where continuous variables were not normally distributed, data transformation (e.g., square-
root transformation) was applied. Mann-Whitney test was used to compare role transitions,
the DAS, and Charlson scores as transforming these data did not fit a normal distribution.
Linear regression was used to determine whether depression vulnerabilities were
significantly associated with a continuous measure of adherence. In the first step,
sociodemographics (age, gender, race, partner status), comorbidity (Charlson), and
depressive symptoms (BDI score) at baseline were entered into the model. Depression
vulnerabilities were then entered individually. We also tested a model in which the
depression vulnerabilities were entered concurrently. As the distribution of medication
adherence was negatively skewed, we performed a sensitivity analysis in which we
transformed our measure of adherence to a measure of non-adherence (i.e., 1 – adherence)
and then applied a square root transformation such that our dependent variable (adherence)
approached a normal distribution. There were no differences in the pattern of association
between depressive symptoms and depression vulnerabilities with medication adherence
when we transformed the adherence variable. Accordingly, for ease of interpretability, we
only present data for the untransformed measure of adherence. We used Preacher and
Hayes’ bootstrap method with 1,000 bootstrap samples to determine whether the depression
vulnerabilities, as a group, mediated the association between depressive symptoms and
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medication adherence.(25) Two-tailed probability levels are reported for all analyses. All
statistical analyses were performed using SPSS 20 (Chicago, Inc.).
Results
The mean age of participants was 59 years, 44% were women, 86% were white, and 65%
had a partner or spouse. The majority of participants were hospitalized for a myocardial
infarction (26% ST-elevation myocardial infarction; 33% non-ST elevation myocardial
infarction, 41% unstable angina). Twenty-seven percent of participants had a prior history of
MI. Thirty percent had a prior history of depression and 20% of participants were prescribed
antidepressants at discharge. The majority of the sample had minimal depressive symptoms
during ACS hospitalization (54% with BDI < 5), 27% had mild to moderate depressive
symptoms (BDI 10–18), and 19% had moderate to severe depressive symptoms (BDI ≥19).
Poor adherence to aspirin (took aspirin correctly on <80% of days) was observed for 23%.
There were no significant differences in sociodemographic characteristics between patients
who had poor (<80%) and good (≥80%) adherence to aspirin (Table 1). Compared to
patients with good adherence, patients with poor adherence had increased comorbidity as
measured by the Charlson score (1.6 SD 1.4 versus 1.2 SD 1.5, P=0.05) and poor adherers
were more likely to be depressed (BDI score ≥10; 63% versus 41%, P=0.01).
Depression Vulnerabilities
There was low correlation between our measures of depression vulnerabilities (correlation
coefficients ranged from −0.07 to 0.21). In bivariate analyses (Table 1), there was a higher
mean number of role transitions in the year prior to the ACS in patients with poor adherence
as compared to patients with good adherence (1.3 SD 1.2 versus 0.7 SD 0.9; p=0.01). There
was also a trend toward the measure of interpersonal conflict (Dyadic Adjustment scale)
being associated with poor medication adherence (p=0.06). In contrast, there were no
significant associations between dysfunctional attitudes or infrequency of pleasant events
with medication adherence (p=0.47 and p=0.48, respectively).
The prevalence of different types of role transitions is shown in Figure 1. The most common
role transitions included a new major health problem other than their cardiovascular disease,
a geographic move, a new job or graduation, and a job loss or retirement. Overall, there was
a higher prevalence of increased role transitions (>1) among patients with poor adherence as
compared to patients with good adherence (41.0% versus 16.5%, P=0.001). Further, there
was a graded association between the number of role transitions in the prior year and
prevalence of poor adherence (Figure 2).
In a model predicting aspirin adherence that included sociodemographics, comorbidity, and
depressive symptoms, only depressive symptoms predicted poor medication adherence
(Table 2). When the depression vulnerabilities were individually added to the model, only
role transitions and interpersonal conflict significantly predicted medication adherence. In
the model that included all the depression vulnerabilities simultaneously, both role
transitions (beta coefficient (SE) −3.32 (1.38); P=0.02) and interpersonal conflict (beta
coefficient (SE) −3.78 (1.74); P=0.03) were associated with poor medication adherence,
whereas dysfunctional attitudes and infrequency of pleasant events were not. The beta
coefficient for the contribution of depressive symptoms to adherence changed little (from
−0.40 to −0.42) when all of the depression vulnerabilities were added to the model. A formal
test of mediation using Preacher and Hayes’ bootstrap approach confirmed that there was no
significant mediation by depression vulnerabilities of the effect of depressive symptoms on
aspirin adherence after ACS.
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The psychosocial context up to one year prior to an ACS - as measured by interpersonal
conflict and the number of major role transitions - was associated with lower adherence to
aspirin after ACS even after accounting for depressive symptoms, sociodemographics, and
comorbidity characteristics. These findings expand upon prior literature showing that
psychosocial factors play an important role in the way patients take their cardiovascular
medications.(26) Prior studies have found an association between major life events and
adherence to medications prescribed for medical illnesses including hypertension and human
immunodeficiency virus.(27–29) Furthermore, when considered alongside the finding that a
measure of interpersonal conflict also predicted worse adherence, the current study
demonstrates that among the potential depression vulnerabilities, psychosocial factors may
be the most impactful on medication adherence.
According to interpersonal theory, the psychosocial factors we measured – major role
transitions and interpersonal conflict – have the potential to cause emotional distress, and
this distress compromises a patients’ ability to handle social roles, which puts them at even
more risk for further negative events.(30, 31) The mechanism(s) by which these
interpersonal factors place patients at risk of poor medication adherence remains unknown,
but we speculate that this cycle of distress leads to deficits in social support and an inability
to maintain healthy habits such as medication adherence. Both social support and habit
strength have been associated with medication adherence in prior studies.(32–36)
Interestingly, adding depression vulnerabilities to the model predicting medication
adherence did not significantly reduce the association between depressive symptoms and
medication adherence and our formal test of mediation confirmed that there was no
mediation by these factors. This finding suggests that the measured psychosocial depression
vulnerabilities (interpersonal conflict and major role transitions) impact medication
adherence independent of depressive symptoms. Holt and colleagues similarly found that
major life events, a measure of psychosocial depression vulnerability similar to our measure
of role transitions, were associated with lower adherence to antihypertensive medications
independent of depression.(27)
In contrast with psychosocial factors, demographic factors were not associated with
medication adherence. This result is consistent with multiple studies that have shown
demographic factors to have little role in predicting who will be adherent to medications.(37,
38)
A major strength of this study includes its use of the gold-standard measure of medication
adherence – electronic measurement - and the careful collection of detailed information
regarding psychological characteristics among patients with cardiovascular disease. There
were also several limitations including a small sample size and the abbreviated range in
depression symptoms for study participants (BDI scores of 5–9 excluded). Furthermore, the
study only measured adherence to aspirin – hence the impact of these depression
vulnerabilities on adherence to the full post-ACS medication regimen remains unknown.
Implications
The current findings highlight the potential importance for clinicians to assess the
psychosocial milieu among post-ACS patients as a means of ascertaining risk of poor
adherence to medications. Clinicians taking care of ACS patients should be mindful of
obtaining histories about the psychosocial context that preceded the ACS event. A particular
focus on recent major life transitions and interpersonal conflict with key members of the
patient’s social network may alert clinicians to the potential for adherence problems. Future
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studies should seek to clarify the mechanisms through which role transitions and
interpersonal conflict impact medication adherence. Interventions that focus on the
resolution of interpersonal conflict and on the promotion of positive adjustment to role
transitions should be formally evaluated to determine whether they can improve adherence
to medications in the post-ACS setting. Approaches that seek to increase the automaticity of
medication-taking behaviors may also be worth testing as they may help patients become
more resilient to challenges from the psychosocial environment.(39)
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Prevalence of Role Transitions in Prior Year among Post-Acute Coronary Syndrome
Patients (N=168)*
*Other major role transitions included events such as death or new major illness in a close
family member or friend, arrival of a new child or grandchild, and arrival or departure of
someone from the household
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Graded Association between Number of Role Transitions and Percentage of Patients with
Poor Adherence (<80%) to Aspirin after Acute Coronary Syndrome
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Table 1
Association between Sociodemographics, Comorbidities, and Depression Vulnerabilities with Adherence to
Aspirin*





Age, mean (SD), years 58.5 (11.2) 59.5 (12.4) 0.64
Female, % 52.6 41.2 0.21
White, % 78.9 88.5 0.13
Partner, % 63.2 65.6 0.78
Prior myocardial infarction, % 42.1 22.6 0.02
Charlson score, mean (SD) 1.6 (1.4) 1.2 (1.5) 0.05a
Prior history of depression, % 43.6 25.6 0.03
Depressed during ACS hospitalization (BDI ≥ 10), % 63.2 40.5 0.01
Number of role transitions, mean (SD) 1.3 (1.2) 0.7 (0.9) 0.01a
Interpersonal conflict (Dyadic Adjustment Scale), mean (SD) 2.5 (1.1) 2.1 (0.7) 0.06a
Cognitive vulnerability (Dysfunctional Attitudes Scale), mean (SD) 76.0 (18.5) 78.7 (22.0) 0.48
Behavioral vulnerability (Pleasant Events Scale for the Elderly), mean
(SD)
0.3 (0.3) 0.3 (0.2) 0.47b
Abbreviations: BDI, Beck Depression Inventory; SD, standard deviation.
*
For the PES-E scale, scores were recoded so that higher scores indicate infrequency of pleasant events. Higher scores on vulnerability scales
indicate increased vulnerability. All displayed descriptive statistics represent values before any transformations were applied to the scales. Chi-
squared tests were used to compare proportions and t-tests were used to compare differences in continuous measures except where specified
otherwise.
aScores were square-root transformed prior to performing the t-test.
b
Mann-Whitney test used for comparison.
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